 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- | Journal: Interaction between Ras and Bcl2L12 in B cells suppresses IL-10 expression. (Pubmed Central) - Sep 19, 2021
In conclusion, Bcl2L12 interacts with Ras activation to compromise immune tolerance in the tonsils by inhibiting the IL-10 expression in tBCs. Inhibition of Bcl2L12 can restore the IL-10 expression in tBCs.
- | Journal: Comprehensive Analysis of Cyclin Family Gene Expression in Colon Cancer. (Pubmed Central) - May 20, 2021
In addition, cyclin genes were highly related to the drug sensitivity of some FDA-approved drugs, such as MEK and EGFR inhibitors, which might provide guidance for clinical treatment. In conclusion, cyclin genes are promising biomarkers for the diagnosis and prognosis of colon cancer.
- | Journal, IO biomarker: Inhibition of Bcl2L12 Attenuates Eosinophilia-Related Inflammation in the Heart. (Pubmed Central) - Apr 20, 2021
The Bcl2L12 expression contributes to apoptosis defects in Eos of the Mcd heart. Blocking Bcl2L12 prevents the eosinophilia induction and alleviates Mcd-like inflammation in mice.
- | Journal, IO biomarker: Identification of Two Novel Circular RNAs Deriving from BCL2L12 and Investigation of Their Potential Value as a Molecular Signature in Colorectal Cancer. (Pubmed Central) - Mar 4, 2021
Interestingly, circ-BCL2L12-2 expression is inversely associated with TNM stage, while circ-BCL2L12-1 overexpression is associated with shorter overall survival in CRC, particularly among TNM stage II patients. Overall, we identified two novel BCL2L12 circRNAs, one of which can further stratify TNM stage II patients into two subgroups with substantially distinct prognosis.
- | Journal: Whole-Exome Sequencing of Nasopharyngeal Carcinoma Families Reveals Novel Variants Potentially Involved in Nasopharyngeal Carcinoma. (Pubmed Central) - Nov 7, 2020
A significant reduction in serum magnesium levels was observed among sporadic NPC cases compared to controls (7.1% NPC/1.7% controls below normal range; OR = 4.5; 95% CI = 1.4,14) and is consistent with findings demonstrating a role for magnesium channeling in T-cell responses to EBV. We identified novel genes associated with NPC that point to new areas of inquiry to better understand genetic factors that determine the fate of viral infections and/or otherwise predisposes to NPC.
- | Journal: Soluble CD83 alleviates experimental allergic rhinitis through modulating antigen-specific Th2 cell property. (Pubmed Central) - Nov 4, 2020
sCD83 contributes to immune homeostasis by regulating CD4 T cell activities. Administration of sCD83 may have translational potential for the treatment of AR or other allergic diseases.
- | Journal: Regulating Bcl2L12 expression in mast cells inhibits food allergy. (Pubmed Central) - Aug 23, 2020
The apoptosis machinery in mast cells is impaired in an allergic environment. Inhibition of Bcl2L12 restores the apoptosis machinery in mast cells in the FA mouse intestine.
- | Journal: Correction: Bcl2L12 Contributes to Th2-Biased Inflammation in the Intestinal Mucosa by Regulating CD4 T Cell Activities. (Pubmed Central) - Aug 1, 2020
Inhibition of Bcl2L12 restores the apoptosis machinery in mast cells in the FA mouse intestine. No abstract available
- | Biomarker, Journal, IO Biomarker: Complex transcriptional regulation of the BCL2L12 gene: novel, active promoter in K562 cells. (Pubmed Central) - Jul 21, 2020
If this novel BCL2L12 promoter is confirmed to be active in other malignancies, transcripts generated from this region could be considered as new cancer-specific biomarkers. The results of our study contribute to the better understanding of the transcriptional regulation of the BCL2L12 gene.
- | Journal: Breathing New Life into TRAIL for Breast Cancer Therapy: Co-delivery of pTRAIL and Complementary siRNAs using Lipopolymers. (Pubmed Central) - Jun 4, 2020
The enhanced anticancer activity was attributed to increased in situ secretion of TRAIL and sensitization of breast cancer cells against TRAIL by the co-delivered siRNAs. The lipid-grafted PEIs capable of co-delivering multiple types of nucleic acids can serve as powerful carriers for more-effective complementary therapeutics.
- || Clinical, Journal: Interleukin-5 induces apoptotic defects in CD4 T cells of patients with allergic rhinitis. (Pubmed Central) - May 7, 2020
In conclusion, overexpression of Bcl2L12 in CD4 T cells compromises the apoptosis machinery; the latter can be restored by inhibition of Bcl2L12. BcL2L12 in CD4 T cells may be a novel target for the treatment of AR and other allergic disorders.
- | Journal: Lamin A/C and Emerin depletion impacts chromatin organization and dynamics in the interphase nucleus. (Pubmed Central) - Mar 12, 2020
BcL2L12 in CD4 T cells may be a novel target for the treatment of AR and other allergic disorders. Taken together, these studies underscore a remarkable interplay between Lamin A/C and Emerin in modulating cytoskeletal organization of actin and NM1 that impinges on chromatin dynamics and function in the interphase nucleus.
- | Journal: Moringin Pretreatment Inhibits the Expression of Genes Involved in Mitophagy in the Stem Cell of the Human Periodontal Ligament. (Pubmed Central) - Jan 28, 2020
The downregulation of the most of the caspases (CASP1 FC: -1.43, CASP4 FC: -0.18, CASP6 FC: -1.34, CASP7 FC: -0.46, CASP8 FC: -0.65) implies the inactivation of the apoptotic process. Our results suggest that mitochondrial dysfunctions induced by oxidative stress can be inhibited by moringin pretreatment in human periodontal ligament stem cells (hPDLSCs).
- || Biomarker, Clinical, Journal, IO Biomarker: Positive BCL2L12 expression predicts favorable prognosis in patients with laryngeal squamous cell carcinoma. (Pubmed Central) - Dec 20, 2019
BCL2L12 protein expression could be used as a favorable prognostic tissue biomarker in patients with primary advanced-stage LSCC. On the contrary, BCL2 and BAX did not correlate with prognosis in patients with primary LSCC.
- | Journal: Bcl2L12 plays a critical role in the development of airway allergy via inducing aberrant T helper-2 polarization. (Pubmed Central) - Nov 14, 2019
On the contrary, BCL2 and BAX did not correlate with prognosis in patients with primary LSCC. Bcl2L12 plays an important role in the pathogenesis of allergic asthma by promoting the differentiation of Th2 cells, which may be a novel therapeutic target in the treatment of allergic asthma.
- | Journal: BCL2L12: a multiply spliced gene with independent prognostic significance in breast cancer. (Pubmed Central) - Oct 29, 2019
Conclusions BCL2L12 v.1, v.2, v.4 are aberrantly expressed in BC. Their expressional analysis by cost-effective molecular methods could provide a novel molecular tool for BC management.
- | Journal, IO Biomarker: Proteinase-activated receptor-2 enhances Bcl2-like protein-12 expression in lung cancer cells to suppress p53 expression. (Pubmed Central) - Oct 3, 2019
PAR2 could attenuate lung cancer cell apoptosis via inducing Bcl2L12. Lung cancer cells express Bcl2L12, which mediates the effects of activation of PAR2 on suppressing the expression of p53 in lung cancer cells, implying that Bcl2L12 may be a novel therapeutic target for the treatment of lung cancer.
- | Journal, IO Biomarker: Bcl2-Like Protein 12 Is Required for the Aberrant T Helper-2 Polarization in the Heart by Enhancing Interleukin-4 Expression and Compromising Apoptotic Machinery in CD4+ T Cells. (Pubmed Central) - Sep 30, 2019
CD4 T cells isolated from hearts with myocarditis at the end stage of heart failure express high levels of Bcl2L12, and the latter is required for the development of aberrant Th2 polarization in the heart. The Bcl2L12 may be a novel target in the treatment of myocarditis as well as other Th2-biased inflammation.
- | Clinical, Journal, IO Biomarker: BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia. (Pubmed Central) - Sep 11, 2019
Lastly, evaluation of BCL2L12 expression clearly strengthened the prognostic value of the established disease prognostic markers, leading to superior prediction of patients' outcome and improved specificity of BFM risk stratification. Conclusions The expression levels of the apoptosis-related BCL2L12 predict response to treatment and survival outcome of childhood ALL patients receiving BFM chemotherapy.
- | Journal: Correction: Bcl2L12 Contributes to Th2-Biased Inflammation in the Intestinal Mucosa by Regulating CD4 T Cell Activities. (Pubmed Central) - Aug 11, 2019
Conclusions The expression levels of the apoptosis-related BCL2L12 predict response to treatment and survival outcome of childhood ALL patients receiving BFM chemotherapy. No abstract available
- | Journal, IO Biomarker: Bcl2L12 plays a critical role in the development of intestinal allergy. (Pubmed Central) - Aug 8, 2019
In conclusion, Bcl2L12 plays a crucial role in the induction of Th2 polarization and allergic response in the intestine. The Bcl2L12 in CD4 T cells may be a potential target for the treatment of FA.
- | Journal: B cell lymphoma-2-like protein-12 association with T-helper 2 inflammation in chronic rhinosinusitis with allergy. (Pubmed Central) - Aug 7, 2019
Bcl2L12 is positively correlated with Th2 cytokine levels in the nasal mucosa of CRSa patients. Bcl2L12 contributes to the Th2 polarization, which may be a novel therapeutic target in the treatment of CRSa.
- | Journal: Long noncoding RNA NEAT1 sponges miR‑125a‑5p to suppress cardiomyocyte apoptosis via BCL2L12. (Pubmed Central) - Aug 1, 2019
Furthermore, the results indicated that NEAT1 inhibits cardiomyocyte apoptosis via regulating the expression of BCL2L12, which appeared to be mediated via miR‑125a‑5p. In conclusion, the present study suggested that NEAT1 functions as a miR sponge to inhibit cardiomyocyte apoptosis and may be a novel therapeutic target for cardiomyocyte apoptosis‑associated heart diseases.
- | Journal, IO Biomarker: Bcl2L12 Contributes to Th2-Biased Inflammation in the Intestinal Mucosa by Regulating CD4 T Cell Activities. (Pubmed Central) - Jul 7, 2019
In conclusion, the Bcl2L12 is a critical factor in the induction of aberrant Th2 polarization by upregulating Th2 responses and downregulating Th2 cell apoptosis. Bcl2L12 may be a novel therapeutic target in the management of the disorders with Th2-biased inflammation.